Short-term versus long-term induction therapy with antithymocyte globulin in orthotopic liver transplantation

Transplant International

Volumn 20, Issue 5, 2007, Pages 447-452

  Soliman, Thomas ^a   Hetz, Hubert ^a   Burghuber, Christoph ^a   Györi, Georg ^a   Silberhumer, Gerd ^a   Steininger, Rudolf ^a   Mühlbacher, Ferdinand ^a   Berlakovich, Gabriela A ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Infection; Liver transplantation; Rejection; Thymoglobulin

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; DEXAMETHASONE; DIPHENHYDRAMINE; DIPYRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; THYMOCYTE ANTIBODY;

ABDOMINAL INFECTION; AGED; ARTICLE; CADAVER DONOR; CHOLANGITIS; CHOLESTASIS; CLINICAL PROTOCOL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; ENTERITIS; ESOPHAGITIS; FEMALE; GRAFT SURVIVAL; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HUMAN TISSUE; INFECTION RATE; LETHALITY; LIVER CELL CARCINOMA; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; ORTHOTOPIC TRANSPLANTATION; PNEUMONIA; PRIORITY JOURNAL; RECURRENT CANCER; RETROSPECTIVE STUDY; RISK FACTOR; SEPSIS; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; WOUND INFECTION;

ADULT; ANTILYMPHOCYTE SERUM; CYCLOSPORINE; DEXAMETHASONE; FEMALE; GLUCOCORTICOIDS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PREDNISOLONE; RETROSPECTIVE STUDIES; VIRUS DISEASES;

EID: 34047213017     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2007.00463.x     Document Type: Article

References (29)

1. Steininger R, Muhlbacher F, Hamilton G, et al. Comparison of CyA, OKT3, and ATG immunoprophylaxis in human liver transplantation. Transplant Proc 1991; 23: 2269.
2. Schulak J, May E, Post A, Fasola C, Mulligan D, Sterling R. Reduction of early rejection in adult liver transplantation with ATG induction therapy. Transplant Proc 1997; 29: 555.
3. Tector AJ, Fridell JA, Mangus RS, et al. Promising early results with immunosuppression using rabbit anti-thymocyte globulin and steroids with delayed introduction of tacrolimus in adult liver transplant recipients. Liver Transpl 2004; 10: 404.
4. Bijleveld CG, Klompmaker IJ, van den Berg AP, et al. Incidence, risk factors, and outcome of antithymocyte globulin treatment of steroid-resistant rejection after liver transplantation. Transpl Int 1996; 9: 570.
5. Morris PJ, Monaco AP. Regulatory T cells finally get the attention they deserve. Transplantation 2004; 77(Suppl. 1): S2.
6. Akamatsu N, Sugawara Y, Kaneko J, et al. Risk factors of cytomegalovirus infection after living donor liver transplantation. Hepatogastroenterology 2005; 52: 197.
7. Hammer C, Thein E. Visualization of the effect of polyclonal antithymocyte globulins on adhesion of leukocytes. Transplant Proc 2002; 34: 2486.
8. Furukawa H, Todo S. Evolution of immunosuppression in liver transplantation: contribution of cyclosporine. Transplant Proc 2004; 36(Suppl. 2): 274S.
9. Mazzaferro V, Regalia E, Doci R. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693.
10. Gruenberger T, Steininger R, Sautner T, Mittlbock M, Muhlbacher F. Influence of donor criteria on postoperative graft function after orthotopic liver transplantation. Transpl Int 1994; 7(Suppl. 1): S672.
11. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997; 25: 658.
12. Soliman T, Berlakovich GA, Steininger R. Liver transplantation for hepatic malignancies. Eur Surg 2006; 38: 63.
13. Toren A, Ilan Y, Or R, Kapelushnik J, Nagler A. Impaired liver function tests in patients treated with antithymocyte globulin: implication for liver transplantation. Med Oncol 1997; 14: 125.
14. McVicar JP, Kowdley KV, Emond MJ, et al. Induction immunosuppressive therapy is associated with a low rejection rate after liver transplantation. Clin Transplant 1997; 11: 328.
15. Ducloux D, Kazory A, Challier B, et al. Long-term toxicity of antithymocyte globulin induction may vary with choice of agent: a single-center retrospective study. Transplantation 2004; 77: 1029.
16. Kamar N, Borde JS, Sandres-Saune K, et al. Induction therapy with either anti-CD25 monoclonal antibodies or rabbit antithymocyte globulins in liver transplantation for hepatitis C. Clin Transplant 2005; 19: 83.
17. Berlakovich GA, Imhof M, Karner-Hanusch J, et al. The importance of the effect of underlying disease on rejection outcomes following orthotopic liver transplantation. Transplantation 1996; 61: 554.
18. Berlakovich GA, Rockenschaub S, Taucher S, Kaserer K, Muhlbacher F, Steininger R. Underlying disease as a predictor for rejection after liver transplantation. Arch Surg 1998; 133: 167.
19. Adams DH, Neuberger JM. Treatment of acute rejection. Semin Liver Dis 1992; 12: 80.
20. Encke J, Uhl W, Stremmel W, Sauer P. Immunosuppression and modulation in liver transplantation. Nephrol Dial Transplant 2004; 19(Suppl. 4): iv22.
21. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4: 222.
22. Jonas S, Neuhaus R, Junge G, et al. Primary immunosuppression with tacrolimus after liver transplantation: 12-years follow-up. Int Immunopharmacol 2005; 5: 125.
23. Cherikh WS, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ, Hanto DW. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003; 76: 1289.
24. Jonas S, Rayes N, Neumann U, et al. De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin. Cancer 1997; 80: 1141.
25. Mark W, Graziadei I, Bargehr D, et al. Infectious complications limit the outcome of liver transplantation in medical urgency code 2 patients. Transplant Proc 2005; 37: 1224.
26. Singh N. Infectious diseases in the liver transplant recipient. Semin Gastrointest Dis 1998; 9: 136.
27. Roayaie S, Schwartz JD, Sung MW, et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl 2004; 10: 534.
28. Pokorny H, Gruenberger T, Soliman T, Rockenschaub S, Langle F, Steininger R. Organ survival after primary dysfunction of liver grafts in clinical orthotopic liver transplantation. Transpl Int 2000; 13(Suppl. 1): S154.
29. St Peter SD, Imber CJ, Friend PJ. Liver and kidney preservation by perfusion. Lancet 2002; 359: 604.